Organization · Venture Capital
Droia Ventures
Droia Ventures is a specialist biotech investor based in Brussels, Belgium, focusing on therapeutics for oncology and genetic diseases. The firm actively supports early-stage drug development companies globally, leveraging innovative science and technology.
Overview
What Droia Ventures does
What Droia Ventures is
Droia Ventures is a specialist biotech investor based in Brussels, Belgium, focusing on therapeutics for oncology and genetic diseases. The firm actively supports early-stage drug development companies globally, leveraging innovative science and technology.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find Droia Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Droia Ventures as a funder
Investment thesis
Droia Ventures targets young drug development companies that utilize novel science and innovative approaches in therapeutics, focusing on oncology and genetic diseases.
Focus narrative
Droia Ventures exclusively invests in therapeutics targeting oncology and genetic diseases. The firm seeks to support companies that tackle previously unsolvable clinical problems through innovative technology platforms or scientific insights, emphasizing significant patient benefits and improvements over existing standard care.
Value beyond capital
Droia Ventures adds value to its portfolio companies through hands-on support, leveraging its expertise in drug development and access to a network of industry contacts. The firm emphasizes collaboration and strategic guidance from company creation through clinical proof of concept, ensuring that its investments are well-positioned for success.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B · Series C
- Regions
- Europe · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 42
Portfolio context
Notable portfolio companies include: Accent Therapeutics: Developing small molecule therapies in epitranscriptomics. Actio Biosciences: Focused on drugs that modulate proteins responsible for rare diseases. Alesta Therapeutics: Developing next-generation kinase inhibitors for rare neuro-related diseases and cancer. Ambagon Therapeutics: Creating first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes. Aura Biosciences: Developing tumor-targeted viral-like nanoparticles for ocular melanoma treatment. Cyteir Therapeutics: Developing synthetic lethal therapies for cancer and autoimmune diseases. Frontier Medicines: Utilizing chemoproteomics and machine learning to target "undruggable" proteins.
Common questions
What to know about Droia Ventures
Upseed classifies Droia Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.